MedTrace Logo

Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia

NCT00169065 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2015-04-07

No results posted yet for this study

Summary

This study will determine the effectiveness of clozapine versus olanzapine in treating people with schizophrenia that has not improved with treatment.

Conditions

Interventions

DRUG

Clozapine

DRUG

Olanzapine

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • Dartmouth-Hitchcock Medical Center

    collaborator OTHER

  • Commonwealth Research Center, Massachusetts

    collaborator OTHER

  • Eli Lilly and Company

    collaborator INDUSTRY

  • Harvard Medical School (HMS and HSDM)

    lead OTHER

Principal Investigators

  • Alan I Green, MD · Harvard Medical School (HMS and HSDM)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-08-31
Primary Completion
2002-06-30
Completion
2002-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00169065 on ClinicalTrials.gov